September 22, 2017 Biometric Monitoring Devices for Objective Assessments of Relevant Endpoints for Clinical Drug Trials: Key Considerations in Developing an Actionable Eco-system
September 11, 2017 C-Path, CHDI Foundation, and CDISC Announce Public Review Period for Huntington’s Disease Therapeutic Area User Guide September 11, 2017 TUCSON, AZ, NEW YORK, NY, and AUSTIN, TX – September 11, 2017 – Critical Path Institute (C-Pa
August 17, 2017 The MSOAC approach to developing performance outcomes to measure and monitor multiple sclerosis disability
August 17, 2017 National MS Society-Supported Collaborators Publish Reviews of Tools Used to Measure MS Progression
July 28, 2017 Dopamine Transporter Neuroimaging as an Enrichment Biomarker in Early Parkinson’s Disease Clinical Trials: A Disease Progression Modeling Analysis Conrado DJ, Nicholas T, Tsai K, Macha S, Sinha V, Stone J, Corrigan B, Bani M, Muglia P, Watson IA, Kern VD, Sheveleva E, Marek K,
July 16, 2017 Landscape analysis of biometric monitoring devices (BMDs) utilized in assessing cognition, sleep and mobility in Alzheimer’s disease and other age-related neurological diseases Kern, V.D., et al.; “Landscape analysis of biometric monitoring devices (BMDs) utilized in assessing cognition, sleep and mobili
July 16, 2017 The Coalition Against Major Diseases: Towards U.S. FDA qualification of hippocampal volume as a biomarker for enrichment in clinical trials for pre-dementia stages of Alzheimer’s disease Conrado, D.J., et al.; “The Coalition Against Major Diseases: Towards U.S. FDA qualification of hippocampal volume as a biomarke
June 30, 2017 D-RSC presents poster and talks about data standards at the Duchenne Connect Conference
